Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT ID: NCT01245231
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying prognostic biomarkers in cell samples from young patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
NCT01024127
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01321385
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
NCT01076569
Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01581528
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia
NCT01290107
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To determine the percentage of primary acute myeloid leukemia (AML) samples with increased Stat3 signaling pathway activity.
* To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3 activation to low- and high-doses of cytokines.
* To evaluate the expression levels of Stat3 protein and the upstream and downstream regulators of Stat3 activation.
Secondary
* To classify samples according to a Stat3 activation pattern and correlate this result with event-free survival (EFS) and overall survival (OS).
OUTLINE: Cryopreserved AML specimens are analyzed for pStat3 and pStat5 levels, response to cytokine levels, and expression level of proteins known to influence stat activity by flow cytometry and western blot assays. Results are also compared with prognostic variables determined in CCG-291 study, including age, race, WBC, and cytogenetic risks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
protein expression analysis
western blotting
flow cytometry
laboratory biomarker analysis
medical chart review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia (AML)
* Cryopreserved AML specimens
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michele S. Redell, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Texas Children's Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML11B6
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000689410
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02845
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML11B6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.